SPOTLIGHT -
EP. 1: Molecular Testing for NSCLC in 2017
EP. 2: EGFR Testing for NSCLC
EP. 3: Treatment for EGFR+ NSCLC
EP. 4: Addition of Bevacizumab to Up-front therapy for EGFR+ NSCLC
EP. 5: Relapsed or Refractory EGFR+ NSCLC
EP. 6: Osimertinib for EGFR T790M Resistance Mutations in NSCLC
EP. 7: Upfront Use of Osimertinib in EGFR+ NSCLC
EP. 8: Progression of ALK+ NSCLC
EP. 9: Upfront Use of Next-Generation ALK Inhibitors in NSCLC
EP. 10: Third-Generation ALK Inhibitors for NSCLC
EP. 11: Upfront Use of Immunotherapy for NCSLC
EP. 12: PD-L1 Testing for NSCLC
EP. 13: New Data for Checkpoint Inhibitors in NSCLC
EP. 14: What to Do After Progression on Immunotherapy and for Non-Driver NSCLC
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
